Prediction workspace
Duquesne Stanley Druckenmiller
Current-position sell-side warning list, trust-gate context, company change signals, and driver targets. This page keeps model risk work separate from the portfolio dashboard.
Latest warning model
Trim / Exit Risk Warnings
62 / 8652 exit · 10 trim · 2026-06-30 to 2026-09-30
65%Recall 69% · 2,136 historical rows
68%36% historical coverage · High-confidence Trim/Exit only
v1.1 hybrid 5 / Baseline 81Trim 10 / Exit 52 current warnings
5 vs baseline36 vs v1.1 hybrid · 81 model switches
+3.3 pts+1.9 pts vs v1.1 hybrid · calibrated 41%
| Name | Warning | Risk evidence | Selected model | Segment evidence | Model agreement | Context | Company |
|---|---|---|---|---|---|---|---|
| WWDWoodward Inc0.55% weight · latest REDUCE | REDUCE 72%Trim warning | Trim/Exit 91%calibrated 43% · 37%-50%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: reduce258 rows · 42% hit rate+3.5 pts vs fallback | Baseline risk 91%Hybrid risk 93%v1.2 risk 86% | Industrials and aerospaceRisk-onneutralmacro 0.90 | neutralmediummedium |
| ARMArm Holdings plc0.19% weight · latest REDUCE | EXIT 79%Exit warning | Trim/Exit 91%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 91%Hybrid risk 65%v1.2 risk 52% | SemiconductorsRisk-onneutralmacro 1.01 | neutralmediumlow |
| TEVATeva Pharmaceutical Industries0.41% weight · latest REDUCE | REDUCE 63%Trim warning | Trim/Exit 90%calibrated 43% · 32%-54%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 90%Hybrid risk 30%v1.2 risk 10% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralmediummedium |
| ARGTGlobal X MSCI Argentina ETF0.58% weight · latest REDUCE | EXIT 74%Exit warning | Trim/Exit 89%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | size macro: small: tailwind215 rows · 51% hit rate+5.1 pts vs fallback | Baseline risk 89%Hybrid risk 29%v1.2 risk 11% | OtherRisk-onneutralmacro 0.25 | neutralneutralunknown |
| WABWestinghouse Air Brake Technol0.29% weight · latest REDUCE | REDUCE 46%Trim warning | Trim/Exit 88%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: reduce258 rows · 42% hit rate+3.5 pts vs fallback | Baseline risk 88%Hybrid risk 88%v1.2 risk 82% | Industrials and aerospaceRisk-onneutralmacro 0.90 | neutralmediummedium |
| AAAlcoa Corp0.19% weight · latest REDUCE | EXIT 65%Exit warning | Trim/Exit 83%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 83%Hybrid risk 79%v1.2 risk 74% | Energy and materialsRisk-onneutralmacro -0.08 | negativemediummedium |
| TXG10X Genomics Inc0.30% weight · latest ADD | EXIT 74%Exit warning | Trim/Exit 81%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 81%Hybrid risk 80%v1.2 risk 73% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralmediummedium |
| TMOThermo Fisher Scientific Inc0.18% weight · latest ADD | EXIT 76%Exit warning | Trim/Exit 80%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 80%Hybrid risk 74%v1.2 risk 66% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutralmedium |
| RDDTReddit Inc0.19% weight · latest ADD | EXIT 75%Exit warning | Trim/Exit 80%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 80%Hybrid risk 95%v1.2 risk 91% | Consumer internet and mediaRisk-onneutralmacro 1.52 | positiveneutralmedium |
| UWMCUWM Holdings Corporation0.11% weight · latest ADD | EXIT 76%Exit warning | Trim/Exit 79%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 79%Hybrid risk 86%v1.2 risk 80% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralmediumlow |
| ROKURoku Inc0.49% weight · latest REDUCE | EXIT 42%Exit warning | Trim/Exit 78%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 78%Hybrid risk 55%v1.2 risk 44% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralmediummedium |
| YPFYPF S.A. ADR2.74% weight · latest HOLD | REDUCE 75%Trim warning | Trim/Exit 77%calibrated 42% · 32%-53%Differs from baseline risk read | v1.1 hybrid 75/25fallback v1.1 hybrid | global2,136 rows · 41% hit rate0.0 pts vs fallback | Baseline risk 9%Hybrid risk 77%v1.2 risk 92% | Energy and materialsRisk-onneutralmacro 0.49 | neutralneutrallow |
| DFTXDefinium Therapeutics Inc.0.32% weight · latest ADD | EXIT 70%Exit warning | Trim/Exit 76%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 76%Hybrid risk 89%v1.2 risk 85% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutrallow |
| RGENRepligen Corp0.20% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 76%Hybrid risk 43%v1.2 risk 31% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutralunknown |
| RKTRocket Companies Inc0.20% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 76%Hybrid risk 93%v1.2 risk 90% | OtherRisk-onneutralmacro 0.83 | neutralneutralunknown |
| FFIVF5 Inc0.18% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 76%Hybrid risk 81%v1.2 risk 75% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralneutralunknown |
| SKESkeena Resources Ltd0.15% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: hold421 rows · 44% hit rate+8.3 pts vs fallback | Baseline risk 76%Hybrid risk 32%v1.2 risk 20% | Energy and materialsRisk-onneutralmacro -0.08 | neutralneutralunknown |
| GLUEMonte Rosa Therapeutics Inc0.14% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 76%Hybrid risk 92%v1.2 risk 90% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutrallow |
| RLAYRelay Therapeutics Inc0.13% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 76%Hybrid risk 92%v1.2 risk 90% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutrallow |
| NVTSNavitas Semiconductor Corp0.11% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 76%Hybrid risk 86%v1.2 risk 81% | SemiconductorsRisk-onneutralmacro 1.01 | neutralneutralunknown |
| FTAIFTAI Aviation Ltd0.10% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | size macro: small: tailwind215 rows · 51% hit rate+5.1 pts vs fallback | Baseline risk 76%Hybrid risk 93%v1.2 risk 91% | OtherRisk-onneutralmacro 0.25 | neutralneutralunknown |
| BEAMBeam Therapeutics Inc0.10% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 76%Hybrid risk 52%v1.2 risk 41% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutralunknown |
| AURAurora Innovation Inc0.08% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 76%Hybrid risk 82%v1.2 risk 77% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralneutralunknown |
| IRENIREN Ltd.0.08% weight · latest ADD | EXIT 72%Exit warning | Trim/Exit 76%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 76%Hybrid risk 83%v1.2 risk 78% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralneutralunknown |
| RSPInvesco S&P 500 Equal Weight E0.30% weight · latest ADD | EXIT 71%Exit warning | Trim/Exit 74%calibrated 51% · 48%-55%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | size macro: small: tailwind215 rows · 51% hit rate+5.1 pts vs fallback | Baseline risk 74%Hybrid risk 75%v1.2 risk 71% | OtherRisk-onneutralmacro 0.25 | neutralneutralunknown |
| INSMInsmed Inc2.92% weight · latest ADD | REDUCE 62%Trim warning | Trim/Exit 72%calibrated 42% · 31%-54%Differs from baseline risk read | v1.1 hybrid 75/25fallback v1.1 hybrid | global2,136 rows · 41% hit rate0.0 pts vs fallback | Baseline risk 11%Hybrid risk 72%v1.2 risk 85% | Healthcare and biotechRisk-onneutralmacro 0.95 | positiveneutralmedium |
| SNDKSandisk Corp1.52% weight · latest REDUCE | REDUCE 51%Trim warning | Trim/Exit 69%calibrated 37% · 31%-44%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 69%Hybrid risk 91%v1.2 risk 90% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralmediummedium |
| HUTHut 8 Corp0.70% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 91%v1.2 risk 90% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralneutrallow |
| FOXFox Corp0.57% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 91%v1.2 risk 90% | Consumer internet and mediaRisk-onneutralmacro 1.52 | neutralneutralunknown |
| CVCOCavco Industries Inc0.47% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 83%v1.2 risk 80% | Consumer internet and mediaRisk-onneutralmacro 1.52 | neutralneutralunknown |
| PURRHyperliquid Strategies Inc.0.44% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | size macro: small: tailwind215 rows · 51% hit rate+5.1 pts vs fallback | Baseline risk 66%Hybrid risk 88%v1.2 risk 89% | OtherRisk-onneutralmacro 0.25 | neutralneutralunknown |
| RMBSRambus Inc0.44% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 86%v1.2 risk 84% | SemiconductorsRisk-onneutralmacro 1.01 | neutralneutralunknown |
| RYTMRhythm Pharmaceuticals Inc0.43% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 66%Hybrid risk 33%v1.2 risk 22% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutralunknown |
| SKYChampion Homes Inc.0.43% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 82%v1.2 risk 79% | Consumer internet and mediaRisk-onneutralmacro 1.52 | neutralneutralunknown |
| RIOTRiot Platforms Inc0.40% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 66%Hybrid risk 88%v1.2 risk 87% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutrallow |
| EQIXEquinix Inc0.37% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 75%v1.2 risk 72% | Software and AI infrastructureRisk-onneutralmacro 1.01 | neutralneutralunknown |
| CCCCCC Intelligent Solutions Hold0.12% weight · latest ADD | EXIT 62%Exit warning | Trim/Exit 66%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 66%Hybrid risk 45%v1.2 risk 36% | Software and AI infrastructureRisk-onneutralmacro 1.01 | negativehighlow |
| EWZiShares MSCI Brazil ETF2.27% weight · latest HOLD | REDUCE 49%Trim warning | Trim/Exit 65%calibrated 32% · 23%-40%Differs from baseline risk read | v1.1 hybrid 75/25fallback v1.1 hybrid | global2,136 rows · 41% hit rate0.0 pts vs fallback | Baseline risk 17%Hybrid risk 65%v1.2 risk 76% | OtherRisk-onneutralmacro 0.25 | neutralneutralunknown |
| LRCXLam Research Corp0.36% weight · latest ADD | EXIT 60%Exit warning | Trim/Exit 65%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 65%Hybrid risk 91%v1.2 risk 91% | SemiconductorsRisk-onneutralmacro 1.01 | neutralmediummedium |
| XENEXenon Pharmaceuticals Inc0.28% weight · latest HOLD | EXIT 60%Exit warning | Trim/Exit 64%calibrated 47% · 36%-57%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 64%Hybrid risk 48%v1.2 risk 41% | Healthcare and biotechRisk-onneutralmacro 0.95 | negativehighmedium |
| BLTEBelite Bio Inc0.31% weight · latest HOLD | EXIT 60%Exit warning | Trim/Exit 64%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 64%Hybrid risk 35%v1.2 risk 25% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutrallow |
| SOLSSolstice Advanced Materials In0.11% weight · latest HOLD | EXIT 60%Exit warning | Trim/Exit 64%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 64%Hybrid risk 80%v1.2 risk 81% | Energy and materialsRisk-onneutralmacro -0.08 | positiveneutralmedium |
| OLMAOlema Pharmaceuticals Inc0.24% weight · latest HOLD | EXIT 59%Exit warning | Trim/Exit 62%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: hold421 rows · 44% hit rate+8.3 pts vs fallback | Baseline risk 62%Hybrid risk 32%v1.2 risk 21% | Healthcare and biotechRisk-onneutralmacro 0.95 | negativehighmedium |
| DBVTDBV Technologies0.12% weight · latest HOLD | EXIT 56%Exit warning | Trim/Exit 59%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 59%Hybrid risk 17%v1.2 risk 5% | Healthcare and biotechRisk-onneutralmacro 0.95 | negativehighmedium |
| VISTVista Energy S.A.B. de C.V0.16% weight · latest HOLD | EXIT 55%Exit warning | Trim/Exit 59%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | size macro: small: tailwind215 rows · 51% hit rate+5.1 pts vs fallback | Baseline risk 59%Hybrid risk 22%v1.2 risk 12% | Energy and materialsRisk-onneutralmacro 0.49 | neutralneutralunknown |
| JBSJBS N.V.0.15% weight · latest HOLD | EXIT 55%Exit warning | Trim/Exit 59%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 59%Hybrid risk 82%v1.2 risk 82% | Consumer internet and mediaRisk-onneutralmacro 1.49 | neutralneutrallow |
| CVNACarvana Co0.19% weight · latest ADD | EXIT 54%Exit warning | Trim/Exit 58%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 58%Hybrid risk 69%v1.2 risk 66% | Consumer internet and mediaRisk-onneutralmacro 1.52 | negativemediummedium |
| BIDUBaidu Inc0.19% weight · latest ADD | EXIT 54%Exit warning | Trim/Exit 58%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 58%Hybrid risk 89%v1.2 risk 90% | Consumer internet and mediaRisk-onneutralmacro 1.78 | neutralneutrallow |
| DHRDanaher Corp0.18% weight · latest ADD | EXIT 54%Exit warning | Trim/Exit 58%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 58%Hybrid risk 88%v1.2 risk 89% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralneutralmedium |
| GGALGrupo Financiero Galicia0.06% weight · latest ADD | EXIT 54%Exit warning | Trim/Exit 58%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 58%Hybrid risk 89%v1.2 risk 91% | FinancialsRisk-onneutralmacro 0.93 | neutralneutralunknown |
| PTGXProtagonist Therapeutics Inc0.49% weight · latest ADD | REDUCE 53%Trim warning | Trim/Exit 58%calibrated 37% · 31%-44%Differs from baseline risk read | v1.1 hybrid 75/25fallback v1.1 hybrid | global2,136 rows · 41% hit rate0.0 pts vs fallback | Baseline risk 32%Hybrid risk 58%v1.2 risk 61% | Healthcare and biotechRisk-onneutralmacro 0.95 | neutralmediummedium |
| LLYLilly(Eli) & Co0.28% weight · latest ADD | EXIT 54%Exit warning | Trim/Exit 57%calibrated 51% · 39%-63%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 57%Hybrid risk 47%v1.2 risk 40% | Healthcare and biotechRisk-onneutralmacro 0.95 | positiveneutralmedium |
| AEVAAeva Technologies Inc0.40% weight · latest ADD | EXIT 47%Exit warning | Trim/Exit 56%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 56%Hybrid risk 62%v1.2 risk 59% | Software and AI infrastructureRisk-onneutralmacro 1.01 | negativemediummedium |
| TBBBBBB Foods Inc2.32% weight · latest REDUCE | REDUCE 46%Trim warning | Trim/Exit 55%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 55%Hybrid risk 42%v1.2 risk 35% | Consumer internet and mediaRisk-onneutralmacro 1.52 | neutralneutrallow |
| LINLinde Plc0.41% weight · latest HOLD | EXIT 48%Exit warning | Trim/Exit 54%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: hold421 rows · 44% hit rate+8.3 pts vs fallback | Baseline risk 54%Hybrid risk 36%v1.2 risk 31% | Energy and materialsRisk-onneutralmacro -0.08 | neutralneutralmedium |
| CAICaris Life Sciences Inc.0.65% weight · latest HOLD | EXIT 47%Exit warning | Trim/Exit 52%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 52%Hybrid risk 48%v1.2 risk 43% | Healthcare and biotechRisk-onneutralmacro 0.95 | positiveneutralmedium |
| NUVBNuvation Bio Inc0.49% weight · latest HOLD | EXIT 47%Exit warning | Trim/Exit 52%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | v11 action: add438 rows · 32% hit rate+3.4 pts vs fallback | Baseline risk 52%Hybrid risk 38%v1.2 risk 32% | Healthcare and biotechRisk-onneutralmacro 0.95 | positiveneutralmedium |
| QQnity Electronics Inc0.39% weight · latest HOLD | EXIT 44%Exit warning | Trim/Exit 52%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 52%Hybrid risk 72%v1.2 risk 72% | SemiconductorsRisk-onneutralmacro 1.01 | neutralmediummedium |
| FLRFluor Corporation0.99% weight · latest ADD | EXIT 45%Exit warning | Trim/Exit 50%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 50%Hybrid risk 87%v1.2 risk 91% | Industrials and aerospaceRisk-onneutralmacro 0.90 | negativemediumlow |
| RVMDRevolution Medicines Inc1.44% weight · latest ADD | REDUCE 38%Trim warning | Trim/Exit 49%calibrated 21% · 10%-31%Differs from baseline risk read | v1.1 hybrid 75/25fallback v1.1 hybrid | global2,136 rows · 41% hit rate0.0 pts vs fallback | Baseline risk 40%Hybrid risk 49%v1.2 risk 48% | Healthcare and biotechRisk-onneutralmacro 0.95 | negativehighmedium |
| BTDRBitdeer Technologies Group.1.24% weight · latest ADD | EXIT 36%Exit warning | Trim/Exit 48%calibrated 21% · 10%-31%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | rules action: exit880 rows · 53% hit rate+7.3 pts vs fallback | Baseline risk 48%Hybrid risk 87%v1.2 risk 93% | OtherRisk-onneutralmacro 0.25 | neutralneutrallow |
| ENTGEntegris Inc0.41% weight · latest ADD | EXIT 41%Exit warning | Trim/Exit 46%calibrated 32% · 23%-40%Agrees with baseline risk read | Baselinefallback v1.1 hybrid | driver liquidity: growth risk-on: easy490 rows · 39% hit rate+3.3 pts vs fallback | Baseline risk 46%Hybrid risk 86%v1.2 risk 91% | SemiconductorsRisk-onneutralmacro 1.01 | positiveneutralmedium |
| Highest risk warnings | Router warning | Selected model | Risk probability stack | Lifecycle |
|---|---|---|---|---|
| WWDWoodward Inc0.55% weight | REDUCE 72%calibrated 43% · medium | Baselinerules action: reduce | Trim/Exit 91%Reduce 72%Exit 19% | maturesmallreducing_streak |
| ARMArm Holdings plc0.19% weight | EXIT 79%calibrated 51% · high | Baselinedriver liquidity: growth risk-on: easy | Trim/Exit 91%Reduce 12%Exit 79% | reentrysmalllatest_reduce |
| TEVATeva Pharmaceutical Industries0.41% weight | REDUCE 63%calibrated 43% · low | Baselinev11 action: add | Trim/Exit 90%Reduce 63%Exit 27% | reentrysmallreducing_streak |
| ARGTGlobal X MSCI Argentina ETF0.58% weight | EXIT 74%calibrated 51% · high | Baselinesize macro: small: tailwind | Trim/Exit 89%Reduce 14%Exit 74% | reentrysmalllatest_reduce |
| WABWestinghouse Air Brake Technol0.29% weight | REDUCE 46%calibrated 32% · low | Baselinerules action: reduce | Trim/Exit 88%Reduce 46%Exit 42% | maturesmallreducing_streak |
| AAAlcoa Corp0.19% weight | EXIT 65%calibrated 47% · low | Baselinerules action: exit | Trim/Exit 83%Reduce 18%Exit 65% | reentrysmalllatest_reduce |
| TXG10X Genomics Inc0.30% weight | EXIT 74%calibrated 51% · high | Baselinerules action: exit | Trim/Exit 81%Reduce 7%Exit 74% | reentrysmalllatest_add |
| TMOThermo Fisher Scientific Inc0.18% weight | EXIT 76%calibrated 51% · high | Baselinerules action: exit | Trim/Exit 80%Reduce 5%Exit 76% | reentrysmalllatest_add |
| RDDTReddit Inc0.19% weight | EXIT 75%calibrated 51% · high | Baselinedriver liquidity: growth risk-on: easy | Trim/Exit 80%Reduce 5%Exit 75% | reentrysmalllatest_add |
| UWMCUWM Holdings Corporation0.11% weight | EXIT 76%calibrated 51% · high | Baselinedriver liquidity: growth risk-on: easy | Trim/Exit 79%Reduce 4%Exit 76% | newsmalllatest_add |
| ROKURoku Inc0.49% weight | EXIT 42%calibrated 32% · low | Baselinedriver liquidity: growth risk-on: easy | Trim/Exit 78%Reduce 36%Exit 42% | developingsmalllatest_reduce |
| YPFYPF S.A. ADR2.74% weight | REDUCE 75%calibrated 42% · low | v1.1 hybrid 75/25global | Trim/Exit 77%Reduce 75%Exit 1% | reentrymediumadding_streak |
This page now shows sell-side warnings only. Non-sell-side predictions are kept out of the current action list because the backtest is strongest for the reduce/exit direction. Visible current warnings are driven by the latest production router plus trust-gate context. Baseline checks are kept internal as supporting evidence only.
Company signals
Company Change Signals
86One local signal per current common holding
833 need manual or macro-source review
27Prioritized for sell-side risk review
464SEC, FMP, Alpha Vantage, and local price facts
75Signals with medium or high evidence quality
| Name | Overall | Earnings | KPI | Co. guidance | Expectations | Tone | Valuation | Risk | Quality | Summary | Factors | Evidence | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRANatera Inc16.60% weight | neutral | negative | positive | explicit guidance | unknown | positive | high | medium | medium69 | Latest SEC periodic filing is 10-Q filed 2026-08-07 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $752.8M for 2026-06-30, +37.7% vs comparison period.Operating income loss narrowed to -$75.8M for 2026-06-30, +31.3% improvement vs comparison period.Net income loss narrowed to -$67.0M for 2026-06-30, +33.7% improvement vs comparison period. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-07Period 2026-06-30.As of 2026-08-07 SEC · Revenue trendpositive +37.7%Revenue $752.8M for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$75.8M+31.3% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$67.0M+33.7% versus comparison period.As of 2026-06-30 Local price · YTD returnpositive +35.3%Latest local close 309.93 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| TSMTaiwan Semiconductor Manufactu5.40% weight | positive | positive | neutral | explicit guidance | positive | positive | medium | low | medium56 | Latest SEC periodic filing is 20-F filed 2026-04-16 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +40.3% YTD return, confirming market momentum but adding valuation pressure.FMP lastQuarter average analyst target implies +38.8% upside/downside versus current price, across 8 target(s). | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-04-16Period 2025-12-31.As of 2026-04-16 Local price · YTD returnpositive +40.3%Latest local close 426.35 on 2026-08-14.As of 2026-08-14 FMP · Analyst target proxypositive +38.8%FMP lastQuarter average analyst target implies +38.8% upside/downside versus current price, across 8 target(s). | auto collected2026-08-15 |
| STMSTMicroelectronics N.V. ADS AD4.46% weight | negative | negative | neutral | explicit guidance | unknown | positive | high | medium | medium48 | Latest SEC periodic filing is 20-F filed 2026-02-26 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +109.3% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $2.84B as of 2025-12-31. | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-02-26Period 2025-12-31.As of 2026-02-26 SEC · Cashpositive $2.84BLatest usable SEC cash fact.As of 2025-12-31 Local price · YTD returnpositive +109.3%Latest local close 54.29 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| INSMInsmed Inc2.92% weight | positive | positive | positive | explicit guidance | unknown | positive | low | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $425.5M for 2026-06-30, +296.1% vs comparison period.Operating income loss narrowed to -$1.5M for 2026-06-30, +99.5% improvement vs comparison period.Net income loss narrowed to -$13.2M for 2026-06-30, +95.9% improvement vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +296.1%Revenue $425.5M for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$1.5M+99.5% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$13.2M+95.9% versus comparison period.As of 2026-06-30 SEC · Cashpositive $544.8MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| YPFYPF S.A. ADR2.74% weight | neutral | positive | neutral | explicit guidance | unknown | positive | medium | low | low41 | Latest SEC periodic filing is 20-F filed 2026-03-26 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +38.4% YTD return, confirming market momentum but adding valuation pressure. | 2 sourcesSEC · Latest filingneutral 20-F filed 2026-03-26Period 2025-12-31.As of 2026-03-26 Local price · YTD returnpositive +38.4%Latest local close 50.05 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| AMZNAmazon.com Inc2.48% weight | positive | positive | positive | explicit guidance | positive | positive | medium | low | high88 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $200.61B for 2026-06-30, +19.6% vs comparison period.Operating income $27.46B for 2026-06-30, +43.2% vs comparison period.Net income $62.65B for 2026-06-30, +244.9% vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-30.As of 2026-07-31 SEC · Revenue trendpositive +19.6%Revenue $200.61B for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $27.46B+43.2% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $62.65B+244.9% versus comparison period.As of 2026-06-30 SEC · Cashpositive $78.21BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| TBBBBBB Foods Inc2.32% weight | neutral | negative | neutral | explicit guidance | unknown | positive | medium | low | low41 | Latest SEC periodic filing is 20-F filed 2026-04-02 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +43.1% YTD return, confirming market momentum but adding valuation pressure. | 2 sourcesSEC · Latest filingneutral 20-F filed 2026-04-02Period 2025-12-31.As of 2026-04-02 Local price · YTD returnpositive +43.1%Latest local close 47.79 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| GOOGLAlphabet Inc. Class A2.31% weight | positive | neutral | positive | No explicit guide | positive | unknown | medium | low | high80 | Latest SEC periodic filing is 10-Q filed 2026-07-23 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $90.23B for 2025-03-31, +12.0% vs comparison period.Operating income $40.77B for 2026-06-30, +30.4% vs comparison period.Net income $112.19B for 2026-06-30, +297.9% vs comparison period. | 8 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-23Period 2026-06-30.As of 2026-07-23 SEC · Revenue trendpositive +12.0%Revenue $90.23B for 2025-03-31.As of 2025-03-31 SEC · Operating incomepositive $40.77B+30.4% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $112.19B+297.9% versus comparison period.As of 2026-06-30 SEC · Cashpositive $55.91BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| EWZiShares MSCI Brazil ETF2.27% weight | neutral | neutral | neutral | Not applicable | Not applicable | Not applicable | Not applicable | neutral | low20 | This looks like an ETF, trust, index product, or macro exposure. Use underlying exposure, flows, country/commodity data, and liquidity rather than company financial statements. | Local price snapshot shows +6.8% YTD return. | 1 sourcesLocal price · YTD returnneutral +6.8%Non-operating security uses macro/market evidence until underlying exposure data is added.As of 2026-08-14 | needs review2026-08-15 |
| STXSeagate Technology Holdings Pl2.26% weight | neutral | positive | positive | explicit guidance | unknown | positive | high | medium | high73 | Latest SEC periodic filing is 10-K filed 2026-08-04 for period 2026-07-03. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $3.11B for 2026-04-03, +44.1% vs comparison period.Operating income $998.0M for 2026-04-03, +131.6% vs comparison period.Net income $748.0M for 2026-04-03, +120.0% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-K filed 2026-08-04Period 2026-07-03.As of 2026-08-04 SEC · Revenue trendpositive +44.1%Revenue $3.11B for 2026-04-03.As of 2026-04-03 SEC · Operating incomepositive $998.0M+131.6% versus comparison period.As of 2026-04-03 SEC · Net incomepositive $748.0M+120.0% versus comparison period.As of 2026-04-03 SEC · Cashpositive $1.70BLatest usable SEC cash fact.As of 2026-07-03 | auto collected2026-08-15 |
| FOXAFox Corp Class A2.21% weight | negative | neutral | negative | neutral | unknown | unknown | unknown | high | low44 | Latest SEC periodic filing is 10-K filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $3.99B for 2026-03-31, -8.6% vs comparison period.Net income $175.0M for 2026-03-31, -50.6% vs comparison period. | 4 sourcesSEC · Latest filingneutral 10-K filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendnegative -8.6%Revenue $3.99B for 2026-03-31.As of 2026-03-31 SEC · Net incomeneutral $175.0M-50.6% versus comparison period.As of 2026-03-31 Local price · YTD returnneutral -5.5%Latest local close 69.04 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| UALUnited Airlines Holdings Inc2.07% weight | positive | positive | positive | explicit guidance | positive | positive | low | low | high88 | Latest SEC periodic filing is 10-Q filed 2026-07-16 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $17.67B for 2026-06-30, +16.0% vs comparison period.Latest SEC cash fact is $10.17B as of 2026-06-30.FMP lastQuarter average analyst target implies +68.0% upside/downside versus current price, across 12 target(s). | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-16Period 2026-06-30.As of 2026-07-16 SEC · Revenue trendpositive +16.0%Revenue $17.67B for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral $1.10B-17.3% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $805.0M-17.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $10.17BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| SESea Ltd2.02% weight | positive | positive | neutral | explicit guidance | unknown | positive | low | low | medium55 | Latest SEC periodic filing is 20-F filed 2026-04-17 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $4.16B as of 2025-12-31. | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-04-17Period 2025-12-31.As of 2026-04-17 SEC · Cashpositive $4.16BLatest usable SEC cash fact.As of 2025-12-31 Local price · YTD returnneutral -4.4%Latest local close 121.94 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| CDWCDW Corp2.01% weight | neutral | neutral | neutral | neutral | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $361.8M as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendneutral +10.0%Revenue $6.57B for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +20.1%Margin change -0.7% points versus comparison period.As of 2026-06-30 SEC · Operating incomeneutral $428.6M+2.0% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $274.4M+1.2% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| NAMSNewAmsterdam Pharma Company NV2.00% weight | negative | positive | negative | No explicit guide | unknown | positive | low | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $424.2M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendnegative -80.7%Revenue $3.7M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$64.9M-82.0% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$64.1M-269.4% versus comparison period.As of 2026-06-30 SEC · Cashpositive $424.2MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| SNDKSandisk Corp1.52% weight | neutral | positive | positive | explicit guidance | unknown | positive | high | medium | high73 | Latest SEC periodic filing is 10-Q filed 2026-05-01 for period 2026-04-03. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $5.95B for 2026-04-03, +251.0% vs comparison period.Gross margin +78.4% for 2026-04-03, +55.8% point change.Operating income $4.11B for 2026-04-03, +318.6% vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-05-01Period 2026-04-03.As of 2026-05-01 SEC · Revenue trendpositive +251.0%Revenue $5.95B for 2026-04-03.As of 2026-04-03 SEC · Gross marginpositive +78.4%Margin change +55.8% points versus comparison period.As of 2026-04-03 SEC · Operating incomepositive $4.11B+318.6% versus comparison period.As of 2026-04-03 SEC · Net incomepositive $3.62B+3127.7% versus comparison period.As of 2026-04-03 | auto collected2026-08-15 |
| RVMDRevolution Medicines Inc1.44% weight | negative | negative | negative | explicit guidance | unknown | negative | high | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Local price snapshot shows +155.8% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $815.4M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendneutral -Revenue $0 for 2024-09-30.As of 2024-09-30 SEC · Operating incomenegative -$505.1M-90.8% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$644.4M-160.1% versus comparison period.As of 2026-06-30 SEC · Cashpositive $815.4MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| BTDRBitdeer Technologies Group.1.24% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | unknown | neutral | low30 | Latest SEC periodic filing is 20-F filed 2026-04-30 for period 2025-12-31. Available SEC XBRL facts are neutral or incomplete for the watched KPI template. | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | 2 sourcesSEC · Latest filingneutral 20-F filed 2026-04-30Period 2025-12-31.As of 2026-04-30 Local price · YTD returnneutral -18.6%Latest local close 9.13 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| CRHCRH Plc1.14% weight | neutral | negative | neutral | explicit guidance | unknown | positive | low | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $3.02B as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendneutral +5.6%Revenue $10.78B for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +39.8%Margin change +0.4% points versus comparison period.As of 2026-06-30 SEC · Operating incomeneutral $2.08B+7.4% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $1.49B+12.7% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| DALDelta Air Lines Inc1.08% weight | positive | neutral | positive | No explicit guide | positive | unknown | medium | low | high80 | Latest SEC periodic filing is 10-Q filed 2026-07-10 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $19.76B for 2026-06-30, +18.7% vs comparison period.Latest SEC cash fact is $4.67B as of 2026-06-30.FMP lastQuarter average analyst target implies +20.7% upside/downside versus current price, across 16 target(s). | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-10Period 2026-06-30.As of 2026-07-10 SEC · Revenue trendpositive +18.7%Revenue $19.76B for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral $1.86B-11.3% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $1.60B-24.7% versus comparison period.As of 2026-06-30 SEC · Cashpositive $4.67BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| FLRFluor Corporation0.99% weight | negative | neutral | negative | No explicit guide | unknown | unknown | medium | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-07 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Operating income $135.0M for 2026-06-30, +619.2% vs comparison period.Latest SEC cash fact is $2.92B as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-07Period 2026-06-30.As of 2026-08-07 SEC · Revenue trendnegative -5.7%Revenue $4.66B for 2018-09-30.As of 2018-09-30 SEC · Operating incomepositive $135.0M+619.2% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $114.0M-95.4% versus comparison period.As of 2026-06-30 SEC · Cashpositive $2.92BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| DHID.R. Horton Inc0.93% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | unknown | low | medium51 | Latest SEC periodic filing is 10-Q filed 2026-07-23 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $2.08B as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-23Period 2026-06-30.As of 2026-07-23 SEC · Revenue trendneutral +0.0%Revenue $9.23B for 2026-06-30.As of 2026-06-30 SEC · Net incomeneutral $904.9M-11.7% versus comparison period.As of 2026-06-30 SEC · Cashpositive $2.08BLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral +3.3%Latest local close 148.81 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| CPNGCoupang Inc0.89% weight | negative | negative | negative | explicit guidance | unknown | positive | low | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $6.11B as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-30.As of 2026-08-04 SEC · Revenue trendneutral +3.9%Revenue $8.86B for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +28.2%Margin change -1.9% points versus comparison period.As of 2026-06-30 SEC · Operating incomenegative -$556.0M-473.2% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$570.0M-1881.2% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| AMDAdvanced Micro Devices Inc0.81% weight | neutral | neutral | positive | neutral | positive | unknown | high | medium | high80 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-27. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $11.54B for 2026-06-27, +50.1% vs comparison period.Gross margin +53.8% for 2026-06-27, +14.0% point change.Operating income $1.99B for 2026-06-27, +1585.1% vs comparison period. | 8 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-27.As of 2026-08-05 SEC · Revenue trendpositive +50.1%Revenue $11.54B for 2026-06-27.As of 2026-06-27 SEC · Gross marginpositive +53.8%Margin change +14.0% points versus comparison period.As of 2026-06-27 SEC · Operating incomepositive $1.99B+1585.1% versus comparison period.As of 2026-06-27 SEC · Net incomepositive $2.30B+163.4% versus comparison period.As of 2026-06-27 | auto collected2026-08-15 |
| PANWPalo Alto Networks Inc0.76% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-06-03 for period 2026-04-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $3.00B for 2026-04-30, +31.1% vs comparison period.Local price snapshot shows +108.6% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $2.36B as of 2026-04-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-06-03Period 2026-04-30.As of 2026-06-03 SEC · Revenue trendpositive +31.1%Revenue $3.00B for 2026-04-30.As of 2026-04-30 SEC · Gross marginnegative +67.6%Margin change -5.4% points versus comparison period.As of 2026-04-30 SEC · Operating incomenegative -$183.0M-183.6% versus comparison period.As of 2026-04-30 SEC · Net incomenegative -$177.0M-167.6% versus comparison period.As of 2026-04-30 | auto collected2026-08-15 |
| CLFCleveland-Cliffs Inc0.76% weight | neutral | positive | positive | explicit guidance | unknown | positive | high | medium | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-23 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Operating income loss narrowed to -$49.0M for 2026-06-30, +90.2% improvement vs comparison period.Net income loss narrowed to -$145.0M for 2026-06-30, +70.2% improvement vs comparison period.Latest SEC cash fact is $70.0M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-23Period 2026-06-30.As of 2026-07-23 SEC · Revenue trendneutral +5.9%Revenue $5.23B for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$49.0M+90.2% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$145.0M+70.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $70.0MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| HUTHut 8 Corp0.70% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $74.9M for 2026-06-30, +81.4% vs comparison period.Local price snapshot shows +86.0% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $233.6M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-30.As of 2026-08-04 SEC · Revenue trendpositive +81.4%Revenue $74.9M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$206.3M-209.8% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$150.2M-209.4% versus comparison period.As of 2026-06-30 SEC · Cashpositive $233.6MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| CAICaris Life Sciences Inc.0.65% weight | positive | positive | positive | explicit guidance | unknown | positive | low | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $263.7M for 2026-06-30, +45.4% vs comparison period.Operating income $26.9M for 2026-06-30, +249.7% vs comparison period.Net income loss narrowed to -$637,000 for 2026-06-30, +99.1% improvement vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendpositive +45.4%Revenue $263.7M for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $26.9M+249.7% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$637,000+99.1% versus comparison period.As of 2026-06-30 SEC · Cashpositive $819.9MLatest usable SEC cash fact.As of 2026-03-31 | auto collected2026-08-15 |
| ARGTGlobal X MSCI Argentina ETF0.58% weight | neutral | neutral | neutral | Not applicable | Not applicable | Not applicable | Not applicable | neutral | low20 | This looks like an ETF, trust, index product, or macro exposure. Use underlying exposure, flows, country/commodity data, and liquidity rather than company financial statements. | Local price snapshot shows -0.5% YTD return. | 1 sourcesLocal price · YTD returnneutral -0.5%Non-operating security uses macro/market evidence until underlying exposure data is added.As of 2026-08-14 | needs review2026-08-15 |
| FOXFox Corp0.57% weight | negative | neutral | negative | neutral | unknown | unknown | unknown | high | low44 | Latest SEC periodic filing is 10-K filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $3.99B for 2026-03-31, -8.6% vs comparison period.Net income $175.0M for 2026-03-31, -50.6% vs comparison period. | 4 sourcesSEC · Latest filingneutral 10-K filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendnegative -8.6%Revenue $3.99B for 2026-03-31.As of 2026-03-31 SEC · Net incomeneutral $175.0M-50.6% versus comparison period.As of 2026-03-31 Local price · YTD returnneutral -5.4%Latest local close 61.41 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| WWDWoodward Inc0.55% weight | positive | positive | positive | explicit guidance | unknown | positive | medium | low | medium69 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $1.11B for 2026-06-30, +21.2% vs comparison period.Net income $146.7M for 2026-06-30, +35.2% vs comparison period.Latest SEC cash fact is $474.9M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendpositive +21.2%Revenue $1.11B for 2026-06-30.As of 2026-06-30 SEC · Net incomepositive $146.7M+35.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $474.9MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral +22.6%Latest local close 370.56 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| NUVBNuvation Bio Inc0.49% weight | positive | positive | positive | explicit guidance | unknown | positive | low | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $31.7M for 2026-06-30, +555.6% vs comparison period.Latest SEC cash fact is $258.6M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +555.6%Revenue $31.7M for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$51.0M+19.7% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$62.8M-6.5% versus comparison period.As of 2026-06-30 SEC · Cashpositive $258.6MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| PTGXProtagonist Therapeutics Inc0.49% weight | neutral | positive | positive | explicit guidance | unknown | negative | high | medium | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $213.5M for 2026-06-30, +3749.2% vs comparison period.Operating income $158.8M for 2026-06-30, +477.6% vs comparison period.Net income $162.8M for 2026-06-30, +568.3% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendpositive +3749.2%Revenue $213.5M for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $158.8M+477.6% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $162.8M+568.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $420.1MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| ROKURoku Inc0.49% weight | positive | positive | positive | explicit guidance | positive | positive | medium | low | high88 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $1.35B for 2026-06-30, +21.9% vs comparison period.Gross margin +49.7% for 2026-06-30, +4.9% point change.Operating income $146.2M for 2026-06-30, +726.5% vs comparison period. | 8 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +21.9%Revenue $1.35B for 2026-06-30.As of 2026-06-30 SEC · Gross marginpositive +49.7%Margin change +4.9% points versus comparison period.As of 2026-06-30 SEC · Operating incomepositive $146.2M+726.5% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $164.2M+1463.5% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| CVCOCavco Industries Inc0.47% weight | neutral | neutral | neutral | neutral | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-27. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $243.2M as of 2026-06-27. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-27.As of 2026-07-31 SEC · Revenue trendneutral +9.5%Revenue $610.0M for 2026-06-27.As of 2026-06-27 SEC · Gross marginneutral +22.1%Margin change -1.2% points versus comparison period.As of 2026-06-27 SEC · Operating incomeneutral $52.8M-12.6% versus comparison period.As of 2026-06-27 SEC · Net incomeneutral $42.3M-18.1% versus comparison period.As of 2026-06-27 | auto collected2026-08-15 |
| ADMAADMA Biologics Inc0.45% weight | neutral | positive | positive | explicit guidance | unknown | positive | low | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Gross margin +69.4% for 2026-06-30, +14.2% point change.Operating income $52.4M for 2026-06-30, +22.5% vs comparison period.Latest SEC cash fact is $136.0M as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendneutral +2.0%Revenue $124.4M for 2026-06-30.As of 2026-06-30 SEC · Gross marginpositive +69.4%Margin change +14.2% points versus comparison period.As of 2026-06-30 SEC · Operating incomepositive $52.4M+22.5% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $37.8M+10.5% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| PURRHyperliquid Strategies Inc.0.44% weight | neutral | neutral | positive | neutral | unknown | unknown | high | medium | medium65 | Latest SEC periodic filing is 10-Q filed 2026-05-08 for period 2026-03-31. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $2.6M for 2026-03-31, +425.2% vs comparison period.Operating income $193.8M for 2026-03-31, +167.4% vs comparison period.Net income $152.5M for 2026-03-31, +150.1% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-05-08Period 2026-03-31.As of 2026-05-08 SEC · Revenue trendpositive +425.2%Revenue $2.6M for 2026-03-31.As of 2026-03-31 SEC · Operating incomepositive $193.8M+167.4% versus comparison period.As of 2026-03-31 SEC · Net incomepositive $152.5M+150.1% versus comparison period.As of 2026-03-31 SEC · Cashpositive $113.1MLatest usable SEC cash fact.As of 2026-03-31 | auto collected2026-08-15 |
| RMBSRambus Inc0.44% weight | negative | neutral | negative | No explicit guide | unknown | unknown | unknown | medium | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-28 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $134.3M as of 2026-03-31. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-28Period 2026-06-30.As of 2026-07-28 SEC · Revenue trendnegative -40.4%Revenue $56.5M for 2018-06-30.As of 2018-06-30 SEC · Operating incomeneutral $61.8M-2.2% versus comparison period.As of 2026-03-31 SEC · Net incomeneutral $59.9M-0.7% versus comparison period.As of 2026-03-31 SEC · Cashpositive $134.3MLatest usable SEC cash fact.As of 2026-03-31 | auto collected2026-08-15 |
| RYTMRhythm Pharmaceuticals Inc0.43% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $71.3M for 2026-06-30, +46.9% vs comparison period.Latest SEC cash fact is $65.6M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-30.As of 2026-08-04 SEC · Revenue trendpositive +46.9%Revenue $71.3M for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$48.6M-7.2% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$49.3M-5.7% versus comparison period.As of 2026-06-30 SEC · Cashpositive $65.6MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| SKYChampion Homes Inc.0.43% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-27. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $784.7M as of 2026-06-27. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-27.As of 2026-08-05 SEC · Revenue trendneutral +1.3%Revenue $710.2M for 2026-06-27.As of 2026-06-27 SEC · Gross marginneutral +25.2%Margin change -1.8% points versus comparison period.As of 2026-06-27 SEC · Operating incomeneutral $60.3M-23.2% versus comparison period.As of 2026-06-27 SEC · Net incomeneutral $49.2M-24.0% versus comparison period.As of 2026-06-27 | auto collected2026-08-15 |
| DAKTDaktronics Inc0.42% weight | negative | negative | neutral | explicit guidance | unknown | positive | medium | medium | high73 | Latest SEC periodic filing is 10-K filed 2026-06-24 for period 2026-05-02. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $181.9M for 2026-01-31, +21.6% vs comparison period.Operating income $1.9M for 2026-01-31, +153.0% vs comparison period.Latest SEC cash fact is $131.6M as of 2026-05-02. | 7 sourcesSEC · Latest filingneutral 10-K filed 2026-06-24Period 2026-05-02.As of 2026-06-24 SEC · Revenue trendpositive +21.6%Revenue $181.9M for 2026-01-31.As of 2026-01-31 SEC · Gross marginneutral +24.0%Margin change -0.6% points versus comparison period.As of 2026-01-31 SEC · Operating incomepositive $1.9M+153.0% versus comparison period.As of 2026-01-31 SEC · Net incomeneutral $3.0M-82.8% versus comparison period.As of 2026-01-31 | auto collected2026-08-15 |
| PCTPureCycle Technologies Inc.0.42% weight | neutral | negative | positive | explicit guidance | unknown | positive | medium | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $4.5M for 2026-06-30, +173.5% vs comparison period.Latest SEC cash fact is $165.2M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +173.5%Revenue $4.5M for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$41.3M+9.4% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$142.2M+1.4% versus comparison period.As of 2026-06-30 SEC · Cashpositive $165.2MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| SCCOSouthern Copper Corporation0.41% weight | positive | positive | positive | explicit guidance | unknown | positive | medium | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $4.29B for 2026-06-30, +40.6% vs comparison period.Operating income $2.62B for 2026-06-30, +65.3% vs comparison period.Net income $621.4M for 2012-03-31, +29.9% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-30.As of 2026-07-31 SEC · Revenue trendpositive +40.6%Revenue $4.29B for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $2.62B+65.3% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $621.4M+29.9% versus comparison period.As of 2012-03-31 SEC · Cashpositive $5.67BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| LINLinde Plc0.41% weight | neutral | neutral | neutral | explicit guidance | unknown | positive | medium | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $4.90B as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-30.As of 2026-07-31 SEC · Revenue trendneutral +9.3%Revenue $9.29B for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral $2.55B+8.5% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $1.93B+9.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $4.90BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| ENTGEntegris Inc0.41% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | high | medium | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-27. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $883.2M for 2026-06-27, +11.5% vs comparison period.Gross margin +47.6% for 2026-06-27, +3.2% point change.Operating income $164.6M for 2026-06-27, +55.1% vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-27.As of 2026-08-04 SEC · Revenue trendpositive +11.5%Revenue $883.2M for 2026-06-27.As of 2026-06-27 SEC · Gross marginpositive +47.6%Margin change +3.2% points versus comparison period.As of 2026-06-27 SEC · Operating incomepositive $164.6M+55.1% versus comparison period.As of 2026-06-27 SEC · Net incomepositive $93.6M+77.3% versus comparison period.As of 2026-06-27 | auto collected2026-08-15 |
| TEVATeva Pharmaceutical Industries0.41% weight | negative | positive | negative | explicit guidance | unknown | positive | medium | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-29 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $3.65B as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-29Period 2026-06-30.As of 2026-07-29 SEC · Revenue trendneutral -0.8%Revenue $4.14B for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +52.0%Margin change +1.6% points versus comparison period.As of 2026-06-30 SEC · Operating incomenegative -$231.0M-150.8% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$576.0M-304.3% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| UUnity Software Inc0.41% weight | neutral | negative | positive | explicit guidance | unknown | positive | low | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $546.5M for 2026-06-30, +23.9% vs comparison period.Gross margin +79.6% for 2026-06-30, +5.5% point change.Operating income loss narrowed to -$32.2M for 2026-06-30, +72.9% improvement vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +23.9%Revenue $546.5M for 2026-06-30.As of 2026-06-30 SEC · Gross marginpositive +79.6%Margin change +5.5% points versus comparison period.As of 2026-06-30 SEC · Operating incomeneutral -$32.2M+72.9% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$23.6M+78.3% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| AEVAAeva Technologies Inc0.40% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | high | medium | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $6.1M for 2026-06-30, +11.3% vs comparison period.Gross margin +35.7% for 2026-06-30, +85.0% point change.Net income loss narrowed to -$79.6M for 2026-06-30, +58.7% improvement vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +11.3%Revenue $6.1M for 2026-06-30.As of 2026-06-30 SEC · Gross marginpositive +35.7%Margin change +85.0% points versus comparison period.As of 2026-06-30 SEC · Operating incomeneutral -$34.6M+1.0% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral -$79.6M+58.7% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| RIOTRiot Platforms Inc0.40% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-10 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $174.2M for 2026-06-30, +13.9% vs comparison period.Local price snapshot shows +50.1% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $471.4M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-10Period 2026-06-30.As of 2026-08-10 SEC · Revenue trendpositive +13.9%Revenue $174.2M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$239.4M-210.8% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$237.2M-208.1% versus comparison period.As of 2026-06-30 SEC · Cashpositive $471.4MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| QQnity Electronics Inc0.39% weight | neutral | positive | positive | explicit guidance | unknown | positive | high | medium | medium69 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $1.43B for 2026-06-30, +22.1% vs comparison period.Local price snapshot shows +74.3% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $961.0M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-30.As of 2026-08-04 SEC · Revenue trendpositive +22.1%Revenue $1.43B for 2026-06-30.As of 2026-06-30 SEC · Net incomeneutral $211.0M+6.0% versus comparison period.As of 2025-09-30 SEC · Cashpositive $961.0MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnpositive +74.3%Latest local close 142.3 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| EQIXEquinix Inc0.37% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | medium | low | medium65 | Latest SEC periodic filing is 10-Q filed 2026-07-29 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $2.62B for 2026-06-30, +16.4% vs comparison period.Operating income $665.0M for 2026-06-30, +34.6% vs comparison period.Net income $479.0M for 2026-06-30, +30.2% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-29Period 2026-06-30.As of 2026-07-29 SEC · Revenue trendpositive +16.4%Revenue $2.62B for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $665.0M+34.6% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $479.0M+30.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $979.0MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| LRCXLam Research Corp0.36% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | high | medium | medium65 | Latest SEC periodic filing is 10-K filed 2026-08-07 for period 2026-06-28. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $5.84B for 2026-03-29, +23.8% vs comparison period.Operating income $2.05B for 2026-03-29, +31.1% vs comparison period.Net income $1.83B for 2026-03-29, +37.2% vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-K filed 2026-08-07Period 2026-06-28.As of 2026-08-07 SEC · Revenue trendpositive +23.8%Revenue $5.84B for 2026-03-29.As of 2026-03-29 SEC · Gross marginneutral +49.8%Margin change +0.8% points versus comparison period.As of 2026-03-29 SEC · Operating incomepositive $2.05B+31.1% versus comparison period.As of 2026-03-29 SEC · Net incomepositive $1.83B+37.2% versus comparison period.As of 2026-03-29 | auto collected2026-08-15 |
| DFTXDefinium Therapeutics Inc.0.32% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium61 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Local price snapshot shows +218.4% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $655.3M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Operating incomenegative -$75.1M-83.5% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$159.0M-271.9% versus comparison period.As of 2026-06-30 SEC · Cashpositive $655.3MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnpositive +218.4%Latest local close 42.63 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| BLTEBelite Bio Inc0.31% weight | neutral | neutral | neutral | explicit guidance | unknown | neutral | medium | low | medium48 | Latest SEC periodic filing is 20-F filed 2026-03-31 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $352.9M as of 2025-12-31. | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-03-31Period 2025-12-31.As of 2026-03-31 SEC · Cashpositive $352.9MLatest usable SEC cash fact.As of 2025-12-31 Local price · YTD returnneutral +1.8%Latest local close 162.8 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| RSPInvesco S&P 500 Equal Weight E0.30% weight | neutral | neutral | neutral | Not applicable | Not applicable | Not applicable | Not applicable | neutral | low20 | This looks like an ETF, trust, index product, or macro exposure. Use underlying exposure, flows, country/commodity data, and liquidity rather than company financial statements. | Local price snapshot shows +16.3% YTD return. | 1 sourcesLocal price · YTD returnneutral +16.3%Non-operating security uses macro/market evidence until underlying exposure data is added.As of 2026-08-14 | needs review2026-08-15 |
| TXG10X Genomics Inc0.30% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-07 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Gross margin +74.5% for 2026-06-30, +2.1% point change.Local price snapshot shows +243.9% YTD return, confirming market momentum but adding valuation pressure. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-07Period 2026-06-30.As of 2026-08-07 SEC · Revenue trendnegative -12.6%Revenue $151.0M for 2026-06-30.As of 2026-06-30 SEC · Gross marginpositive +74.5%Margin change +2.1% points versus comparison period.As of 2026-06-30 SEC · Operating incomenegative -$19.6M-164.9% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$17.9M-151.9% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| WABWestinghouse Air Brake Technol0.29% weight | positive | positive | positive | explicit guidance | unknown | positive | medium | low | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-22 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $3.18B for 2026-06-30, +17.5% vs comparison period.Operating income $600.0M for 2026-06-30, +27.1% vs comparison period.Net income $395.0M for 2026-06-30, +17.6% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-22Period 2026-06-30.As of 2026-07-22 SEC · Revenue trendpositive +17.5%Revenue $3.18B for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +36.5%Margin change +1.9% points versus comparison period.As of 2026-06-30 SEC · Operating incomepositive $600.0M+27.1% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $395.0M+17.6% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| LLYLilly(Eli) & Co0.28% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | unknown | low | medium51 | Latest SEC periodic filing is 10-Q filed 2026-08-05 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $22.97B for 2026-06-30, +47.7% vs comparison period.Net income $7.09B for 2026-06-30, +25.3% vs comparison period.Latest SEC cash fact is $8.95B as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-05Period 2026-06-30.As of 2026-08-05 SEC · Revenue trendpositive +47.7%Revenue $22.97B for 2026-06-30.As of 2026-06-30 SEC · Net incomepositive $7.09B+25.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $8.95BLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral +9.8%Latest local close 1180.16 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| XENEXenon Pharmaceuticals Inc0.28% weight | negative | negative | negative | explicit guidance | unknown | positive | medium | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Local price snapshot shows +39.1% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $119.5M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendneutral -Revenue $264,000 for 2017-09-30.As of 2017-09-30 SEC · Operating incomenegative -$123.2M-30.7% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$110.7M-30.7% versus comparison period.As of 2026-06-30 SEC · Cashpositive $119.5MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| OLMAOlema Pharmaceuticals Inc0.24% weight | negative | negative | negative | neutral | unknown | neutral | low | high | medium69 | Latest SEC periodic filing is 10-Q filed 2026-08-10 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $48.6M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-10Period 2026-06-30.As of 2026-08-10 SEC · Operating incomenegative -$67.2M-40.4% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$63.2M-44.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $48.6MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnnegative -57.5%Latest local close 10.63 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| RGENRepligen Corp0.20% weight | negative | neutral | negative | No explicit guide | unknown | unknown | unknown | medium | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-29 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $44.8M for 2018-03-31, +46.6% vs comparison period.Latest SEC cash fact is $606.8M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-29Period 2026-06-30.As of 2026-07-29 SEC · Revenue trendpositive +46.6%Revenue $44.8M for 2018-03-31.As of 2018-03-31 SEC · Operating incomeneutral $14.0M+0.6% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $5.0M-66.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $606.8MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| RKTRocket Companies Inc0.20% weight | positive | neutral | positive | No explicit guide | unknown | unknown | low | low | medium54 | Latest SEC periodic filing is 10-Q filed 2026-08-07 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Net income $230.0M for 2026-06-30, +11600.0% vs comparison period.Latest SEC cash fact is $3.10B as of 2026-06-30. | 4 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-07Period 2026-06-30.As of 2026-08-07 SEC · Net incomepositive $230.0M+11600.0% versus comparison period.As of 2026-06-30 SEC · Cashpositive $3.10BLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral -23.8%Latest local close 14.76 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| BIDUBaidu Inc0.19% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | low | low | low40 | Latest SEC periodic filing is 20-F filed 2026-03-17 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Latest SEC cash fact is $3.52B as of 2025-12-31. | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-03-17Period 2025-12-31.As of 2026-03-17 SEC · Cashpositive $3.52BLatest usable SEC cash fact.As of 2025-12-31 Local price · YTD returnneutral -20.7%Latest local close 103.67 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| ARMArm Holdings plc0.19% weight | neutral | neutral | neutral | explicit guidance | unknown | positive | high | medium | medium55 | Latest SEC periodic filing is 20-F filed 2026-05-26 for period 2026-03-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +155.6% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $2.75B as of 2026-03-31. | 3 sourcesSEC · Latest filingneutral 20-F filed 2026-05-26Period 2026-03-31.As of 2026-05-26 SEC · Cashpositive $2.75BLatest usable SEC cash fact.As of 2026-03-31 Local price · YTD returnpositive +155.6%Latest local close 279.44 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| CVNACarvana Co0.19% weight | neutral | neutral | neutral | neutral | unknown | unknown | unknown | medium | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-29 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $7.38B for 2026-06-30, +52.4% vs comparison period.Operating income $680.0M for 2026-06-30, +33.1% vs comparison period.Net income $310.0M for 2026-06-30, +69.4% vs comparison period. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-29Period 2026-06-30.As of 2026-07-29 SEC · Revenue trendpositive +52.4%Revenue $7.38B for 2026-06-30.As of 2026-06-30 SEC · Gross marginnegative +18.8%Margin change -3.2% points versus comparison period.As of 2026-06-30 SEC · Operating incomepositive $680.0M+33.1% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $310.0M+69.4% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| RDDTReddit Inc0.19% weight | positive | neutral | positive | No explicit guide | unknown | unknown | low | low | medium65 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $804.9M for 2026-06-30, +61.1% vs comparison period.Operating income $231.7M for 2026-06-30, +242.2% vs comparison period.Net income $252.8M for 2026-06-30, +183.2% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-30.As of 2026-07-31 SEC · Revenue trendpositive +61.1%Revenue $804.9M for 2026-06-30.As of 2026-06-30 SEC · Operating incomepositive $231.7M+242.2% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $252.8M+183.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $1.49BLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| AAAlcoa Corp0.19% weight | positive | positive | positive | explicit guidance | unknown | positive | medium | low | medium69 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $3.97B for 2026-06-30, +31.4% vs comparison period.Net income $407.0M for 2026-06-30, +148.2% vs comparison period.Latest SEC cash fact is $1.35B as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendpositive +31.4%Revenue $3.97B for 2026-06-30.As of 2026-06-30 SEC · Net incomepositive $407.0M+148.2% versus comparison period.As of 2026-06-30 SEC · Cashpositive $1.35BLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral -5.9%Latest local close 49.98 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| TMOThermo Fisher Scientific Inc0.18% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-27. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $11.99B for 2026-06-27, +10.5% vs comparison period.Latest SEC cash fact is $4.06B as of 2026-06-27. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-27.As of 2026-07-31 SEC · Revenue trendpositive +10.5%Revenue $11.99B for 2026-06-27.As of 2026-06-27 SEC · Operating incomeneutral $2.09B+13.8% versus comparison period.As of 2026-06-27 SEC · Net incomeneutral $1.74B+7.4% versus comparison period.As of 2026-06-27 SEC · Cashpositive $4.06BLatest usable SEC cash fact.As of 2026-06-27 | auto collected2026-08-15 |
| DHRDanaher Corp0.18% weight | neutral | neutral | positive | neutral | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-21 for period 2026-06-26. Fundamental signals skew positive based on available SEC XBRL facts. | Operating income $1.13B for 2026-06-26, +48.3% vs comparison period.Net income $870.0M for 2026-06-26, +56.8% vs comparison period. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-21Period 2026-06-26.As of 2026-07-21 SEC · Revenue trendneutral +5.5%Revenue $6.26B for 2026-06-26.As of 2026-06-26 SEC · Gross marginneutral +57.6%Margin change -1.7% points versus comparison period.As of 2026-06-26 SEC · Operating incomepositive $1.13B+48.3% versus comparison period.As of 2026-06-26 SEC · Net incomepositive $870.0M+56.8% versus comparison period.As of 2026-06-26 | auto collected2026-08-15 |
| FFIVF5 Inc0.18% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | high | medium | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $865.1M for 2026-06-30, +10.9% vs comparison period.Local price snapshot shows +58.0% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $1.61B as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendpositive +10.9%Revenue $865.1M for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +82.2%Margin change +1.3% points versus comparison period.As of 2026-06-30 SEC · Operating incomeneutral $213.3M+8.6% versus comparison period.As of 2026-06-30 SEC · Net incomeneutral $208.2M+9.6% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| VISTVista Energy S.A.B. de C.V0.16% weight | neutral | neutral | neutral | explicit guidance | unknown | positive | medium | low | medium48 | Latest SEC periodic filing is 20-F filed 2026-04-28 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +40.4% YTD return, confirming market momentum but adding valuation pressure. | 2 sourcesSEC · Latest filingneutral 20-F filed 2026-04-28Period 2025-12-31.As of 2026-04-28 Local price · YTD returnpositive +40.4%Latest local close 68.31 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| SKESkeena Resources Ltd0.15% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | medium | low | low33 | Latest SEC periodic filing is 40-F filed 2026-03-24 for period 2025-12-31. Fundamental signals skew positive based on available SEC XBRL facts. | Local price snapshot shows +39.3% YTD return, confirming market momentum but adding valuation pressure. | 2 sourcesSEC · Latest filingneutral 40-F filed 2026-03-24Period 2025-12-31.As of 2026-03-24 Local price · YTD returnpositive +39.3%Latest local close 33.06 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| JBSJBS N.V.0.15% weight | neutral | neutral | neutral | explicit guidance | unknown | positive | high | medium | medium48 | Latest SEC periodic filing is 10-Q filed 2026-08-10 for period 2026-06-30. Available SEC XBRL facts are neutral or incomplete for the watched KPI template. | Identify whether the company's core operating drivers are improving enough to support continued ownership. | 2 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-10Period 2026-06-30.As of 2026-08-10 Local price · YTD returnneutral -5.3%Latest local close 13.65 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| GLUEMonte Rosa Therapeutics Inc0.14% weight | negative | neutral | negative | No explicit guide | unknown | unknown | unknown | high | medium51 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $90.1M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Operating incomenegative -$49.1M-215.9% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$43.4M-253.0% versus comparison period.As of 2026-06-30 SEC · Cashpositive $90.1MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral -1.1%Latest local close 15.5 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| RLAYRelay Therapeutics Inc0.13% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-06 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Local price snapshot shows +134.8% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $121.2M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-06Period 2026-06-30.As of 2026-08-06 SEC · Revenue trendnegative -48.3%Revenue $350,000 for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$90.8M-18.2% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$83.7M-18.9% versus comparison period.As of 2026-06-30 SEC · Cashpositive $121.2MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| DBVTDBV Technologies0.12% weight | negative | negative | negative | explicit guidance | unknown | positive | low | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-16 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $174.9M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-16Period 2026-06-30.As of 2026-07-16 SEC · Revenue trendnegative -53.3%Revenue $700,000 for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$50.6M-23.1% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$50.4M-20.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $174.9MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| CCCCCC Intelligent Solutions Hold0.12% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | unknown | low | medium55 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | Operating income $47.6M for 2026-06-30, +94.7% vs comparison period.Net income $20.8M for 2026-06-30, +60.4% vs comparison period.Latest SEC cash fact is $115.9M as of 2026-06-30. | 7 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendneutral +9.8%Revenue $285.9M for 2026-06-30.As of 2026-06-30 SEC · Gross marginneutral +73.7%Margin change -0.8% points versus comparison period.As of 2026-06-30 SEC · Operating incomepositive $47.6M+94.7% versus comparison period.As of 2026-06-30 SEC · Net incomepositive $20.8M+60.4% versus comparison period.As of 2026-06-30 | auto collected2026-08-15 |
| UWMCUWM Holdings Corporation0.11% weight | negative | neutral | negative | neutral | unknown | unknown | low | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-08-07 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $888.0M for 2026-06-30, +17.0% vs comparison period.Latest SEC cash fact is $498.4M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-07Period 2026-06-30.As of 2026-08-07 SEC · Revenue trendpositive +17.0%Revenue $888.0M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$5.4M-25279.9% versus comparison period.As of 2020-09-30 SEC · Net incomenegative -$80.6M-451.8% versus comparison period.As of 2026-06-30 SEC · Cashpositive $498.4MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| NVTSNavitas Semiconductor Corp0.11% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-07-27 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Local price snapshot shows +102.4% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $557.4M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-27Period 2026-06-30.As of 2026-07-27 SEC · Revenue trendnegative -27.3%Revenue $10.5M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$27.2M-25.6% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$18.7M-349.1% versus comparison period.As of 2024-09-30 SEC · Cashpositive $557.4MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| SOLSSolstice Advanced Materials In0.11% weight | neutral | negative | positive | explicit guidance | unknown | positive | medium | low | medium69 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $1.15B for 2026-06-30, +11.1% vs comparison period.Net income $119.0M for 2026-06-30, +22.7% vs comparison period.Latest SEC cash fact is $750.0M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendpositive +11.1%Revenue $1.15B for 2026-06-30.As of 2026-06-30 SEC · Net incomepositive $119.0M+22.7% versus comparison period.As of 2026-06-30 SEC · Cashpositive $750.0MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral +29.0%Latest local close 62.65 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| FTAIFTAI Aviation Ltd0.10% weight | neutral | neutral | positive | No explicit guide | unknown | unknown | unknown | low | medium51 | Latest SEC periodic filing is 10-Q filed 2026-07-31 for period 2026-06-30. Fundamental signals skew positive based on available SEC XBRL facts. | SEC XBRL revenue $953.1M for 2026-06-30, +40.9% vs comparison period.Net income $58.8M for 2022-09-30, +26.3% vs comparison period.Latest SEC cash fact is $337.2M as of 2026-06-30. | 5 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-31Period 2026-06-30.As of 2026-07-31 SEC · Revenue trendpositive +40.9%Revenue $953.1M for 2026-06-30.As of 2026-06-30 SEC · Net incomepositive $58.8M+26.3% versus comparison period.As of 2022-09-30 SEC · Cashpositive $337.2MLatest usable SEC cash fact.As of 2026-06-30 Local price · YTD returnneutral +10.3%Latest local close 217.13 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| BEAMBeam Therapeutics Inc0.10% weight | negative | neutral | negative | No explicit guide | unknown | unknown | unknown | high | medium55 | Latest SEC periodic filing is 10-Q filed 2026-08-04 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $219.8M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-08-04Period 2026-06-30.As of 2026-08-04 SEC · Revenue trendnegative -94.2%Revenue $490,000 for 2026-06-30.As of 2026-06-30 SEC · Operating incomeneutral -$126.6M-5.3% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$122.7M-20.1% versus comparison period.As of 2026-06-30 SEC · Cashpositive $219.8MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| AURAurora Innovation Inc0.08% weight | negative | neutral | negative | No explicit guide | unknown | unknown | high | high | medium65 | Latest SEC periodic filing is 10-Q filed 2026-07-29 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | SEC XBRL revenue $2.0M for 2026-06-30, +100.0% vs comparison period.Local price snapshot shows +82.0% YTD return, confirming market momentum but adding valuation pressure.Latest SEC cash fact is $136.0M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-29Period 2026-06-30.As of 2026-07-29 SEC · Revenue trendpositive +100.0%Revenue $2.0M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$266.0M-15.7% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$270.0M-34.3% versus comparison period.As of 2026-06-30 SEC · Cashpositive $136.0MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
| IRENIREN Ltd.0.08% weight | negative | neutral | negative | No explicit guide | unknown | unknown | unknown | high | medium55 | Latest SEC periodic filing is 10-Q filed 2026-05-08 for period 2026-03-31. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $2.21B as of 2026-03-31. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-05-08Period 2026-03-31.As of 2026-05-08 SEC · Revenue trendneutral -0.0%Revenue $144.8M for 2026-03-31.As of 2026-03-31 SEC · Operating incomenegative -$233.5M-899.3% versus comparison period.As of 2026-03-31 SEC · Net incomenegative -$247.8M-59.5% versus comparison period.As of 2026-03-31 SEC · Cashpositive $2.21BLatest usable SEC cash fact.As of 2026-03-31 | auto collected2026-08-15 |
| GGALGrupo Financiero Galicia0.06% weight | neutral | neutral | neutral | No explicit guide | unknown | unknown | unknown | neutral | low23 | Latest SEC periodic filing is 20-F filed 2026-04-16 for period 2025-12-31. Available SEC XBRL facts are neutral or incomplete for the watched KPI template. | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | 2 sourcesSEC · Latest filingneutral 20-F filed 2026-04-16Period 2025-12-31.As of 2026-04-16 Local price · YTD returnneutral -19.6%Latest local close 43.37 on 2026-08-14.As of 2026-08-14 | auto collected2026-08-15 |
| WVEWave Life Sciences Ltd.0.02% weight | negative | positive | negative | explicit guidance | unknown | negative | low | high | high73 | Latest SEC periodic filing is 10-Q filed 2026-07-30 for period 2026-06-30. Fundamental signals need caution based on available SEC XBRL facts. | Latest SEC cash fact is $368.0M as of 2026-06-30. | 6 sourcesSEC · Latest filingneutral 10-Q filed 2026-07-30Period 2026-06-30.As of 2026-07-30 SEC · Revenue trendnegative -73.9%Revenue $2.3M for 2026-06-30.As of 2026-06-30 SEC · Operating incomenegative -$73.8M-39.9% versus comparison period.As of 2026-06-30 SEC · Net incomenegative -$69.4M-37.4% versus comparison period.As of 2026-06-30 SEC · Cashpositive $368.0MLatest usable SEC cash fact.As of 2026-06-30 | auto collected2026-08-15 |
This local signal layer separates company guidance from analyst expectations, then applies evidence-quality scoring before it affects the prediction model.
Company drivers
Company Driver Targets
86Current Duquesne common-share holdings
4Manual override templates in v0.1
7Need company-level review first
KPI draftDefines what to watch before scoring recent company change
| Name | Basis | Driver target | Primary KPIs | Earnings triggers | Key risks | Valuation |
|---|---|---|---|---|---|---|
| NTRANatera Inc16.60% weight | Tickerdraft | Confirm that testing volume, oncology adoption, gross margin, and revenue guidance continue to validate the growth thesis. | Test volume growthOncology revenue growthGross marginCash burnRevenue guidance | Test volume and oncology revenue accelerateFull-year revenue guidance is raisedGross margin improves while cash burn narrows | Reimbursement pressureLitigation/regulatory riskCompetition | ntm_ev_salesrevenue_growth_adjusted_psgross_margin_path |
| TSMTaiwan Semiconductor Manufactu5.40% weight | Tickerdraft | Confirm that AI/HPC demand and leading-edge utilization offset cyclicality and geopolitical risk. | HPC/AI revenue growthGross marginCapex/capacity planAdvanced-node mixGuidance revision | AI/HPC revenue and margin outlook improveAdvanced-node utilization risesCapex plan supports durable demand | Taiwan geopolitical riskSmartphone cycle weaknessCapex intensity | ntm_peev_ebitdacapex_adjusted_fcf |
| STMSTMicroelectronics N.V. ADS AD4.46% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| INSMInsmed Inc2.92% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| YPFYPF S.A. ADR2.74% weight | Industrydraft | Confirm that cash flow and capital allocation stay strong across the commodity cycle. | Oil/gas price realizationProduction growthFree cash flowCapex disciplineBuyback/dividend | Oil/gas price backdrop improvesProduction and FCF beat expectationsBuyback or dividend intensity rises | Oil price declinePolitical/regulatory riskCapex inflation | ev_ebitdafcf_yieldnet_debt_to_ebitda |
| AMZNAmazon.com Inc2.48% weight | Tickerdraft | Confirm that AWS and advertising growth improve while retail margins keep expanding. | AWS revenue growthAWS marginAdvertising growthRetail operating marginAI capex commentary | AWS growth reacceleratesRetail and advertising margins expandAI capex supports future revenue without hurting FCF too much | Cloud competitionAI capex burdenConsumer slowdown | sum_of_partsntm_ev_ebitdafcf_yield |
| TBBBBBB Foods Inc2.32% weight | Sectordraft | Confirm that demand and margins improve without excessive valuation pressure. | Same-store/revenue growthGross marginOperating marginTraffic/ordersGuidance revision | Revenue and traffic/orders accelerateMargins expandGuidance improves | Consumer slowdownPromotional intensityInput cost pressure | ntm_peev_ebitdantm_ev_sales |
| GOOGLAlphabet Inc. Class A2.31% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| EWZiShares MSCI Brazil ETF2.27% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| STXSeagate Technology Holdings Pl2.26% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| FOXAFox Corp Class A2.21% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| UALUnited Airlines Holdings Inc2.07% weight | Tickerdraft | Confirm that unit revenue and margins improve enough to offset fuel, labor, and cycle risk. | Unit revenueCapacity growthFuel costOperating marginFCF/debt | Unit revenue and load factor improveFuel or labor cost pressure easesCapacity discipline holds | Fuel spikeRecession/travel slowdownLabor cost inflation | ntm_peev_ebitdafcf_yield |
| SESea Ltd2.02% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| CDWCDW Corp2.01% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| NAMSNewAmsterdam Pharma Company NV2.00% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| SNDKSandisk Corp1.52% weight | Industrydraft | Track whether order growth, backlog, and margins confirm a hardware cycle upswing. | Orders/backlogRevenue growthGross marginInventoryGuidance revision | Backlog/orders accelerateAI, optical, networking, or storage demand strengthensGross margin expands | Hardware cycle reversalCustomer concentrationInventory correction | ntm_peev_ebitdantm_ev_sales |
| RVMDRevolution Medicines Inc1.44% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| BTDRBitdeer Technologies Group.1.24% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| CRHCRH Plc1.14% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| DALDelta Air Lines Inc1.08% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| FLRFluor Corporation0.99% weight | Sectordraft | Confirm that backlog, margins, and guidance support continued earnings growth. | Orders/backlogOrganic revenue growthOperating marginBook-to-billGuidance revision | Orders/backlog and margins improveBook-to-bill remains above oneGuidance is raised | Industrial cycle slowdownSupply-chain issuesInput cost pressure | ntm_peev_ebitdafcf_yield |
| DHID.R. Horton Inc0.93% weight | Sectordraft | Confirm that demand and margins improve without excessive valuation pressure. | Same-store/revenue growthGross marginOperating marginTraffic/ordersGuidance revision | Revenue and traffic/orders accelerateMargins expandGuidance improves | Consumer slowdownPromotional intensityInput cost pressure | ntm_peev_ebitdantm_ev_sales |
| CPNGCoupang Inc0.89% weight | Industrydraft | Confirm that growth and unit economics improve together. | GMV/revenue growthTake rate/ads monetizationOperating marginUsers/ordersGuidance revision | GMV/revenue accelerates with margin expansionAds, logistics, or marketplace monetization improvesConsumer demand weakens or competition rises | Consumer slowdownCompetitionLogistics cost inflation | ntm_ev_salesntm_peebit_margin_path |
| AMDAdvanced Micro Devices Inc0.81% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| PANWPalo Alto Networks Inc0.76% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| CLFCleveland-Cliffs Inc0.76% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| HUTHut 8 Corp0.70% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| CAICaris Life Sciences Inc.0.65% weight | Industrydraft | Track whether utilization, reimbursement, and operating margins support durable earnings growth. | Volume/member growthReimbursement/pricingCost ratio/service costsOperating marginGuidance revision | Volume/member growth acceleratesMargins improve or cost ratio fallsReimbursement or utilization outlook changes | Reimbursement pressurePolicy riskCost inflation | ntm_peev_ebitdarevenue_growth_adjusted_multiple |
| ARGTGlobal X MSCI Argentina ETF0.58% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| FOXFox Corp0.57% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| WWDWoodward Inc0.55% weight | Sectordraft | Confirm that backlog, margins, and guidance support continued earnings growth. | Orders/backlogOrganic revenue growthOperating marginBook-to-billGuidance revision | Orders/backlog and margins improveBook-to-bill remains above oneGuidance is raised | Industrial cycle slowdownSupply-chain issuesInput cost pressure | ntm_peev_ebitdafcf_yield |
| NUVBNuvation Bio Inc0.49% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| PTGXProtagonist Therapeutics Inc0.49% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| ROKURoku Inc0.49% weight | Industrydraft | Track whether order growth, backlog, and margins confirm a hardware cycle upswing. | Orders/backlogRevenue growthGross marginInventoryGuidance revision | Backlog/orders accelerateAI, optical, networking, or storage demand strengthensGross margin expands | Hardware cycle reversalCustomer concentrationInventory correction | ntm_peev_ebitdantm_ev_sales |
| CVCOCavco Industries Inc0.47% weight | Sectordraft | Confirm that demand and margins improve without excessive valuation pressure. | Same-store/revenue growthGross marginOperating marginTraffic/ordersGuidance revision | Revenue and traffic/orders accelerateMargins expandGuidance improves | Consumer slowdownPromotional intensityInput cost pressure | ntm_peev_ebitdantm_ev_sales |
| ADMAADMA Biologics Inc0.45% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| PURRHyperliquid Strategies Inc.0.44% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| RMBSRambus Inc0.44% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| RYTMRhythm Pharmaceuticals Inc0.43% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| SKYChampion Homes Inc.0.43% weight | Sectordraft | Confirm that demand and margins improve without excessive valuation pressure. | Same-store/revenue growthGross marginOperating marginTraffic/ordersGuidance revision | Revenue and traffic/orders accelerateMargins expandGuidance improves | Consumer slowdownPromotional intensityInput cost pressure | ntm_peev_ebitdantm_ev_sales |
| DAKTDaktronics Inc0.42% weight | Industrydraft | Track whether order growth, backlog, and margins confirm a hardware cycle upswing. | Orders/backlogRevenue growthGross marginInventoryGuidance revision | Backlog/orders accelerateAI, optical, networking, or storage demand strengthensGross margin expands | Hardware cycle reversalCustomer concentrationInventory correction | ntm_peev_ebitdantm_ev_sales |
| PCTPureCycle Technologies Inc.0.42% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| SCCOSouthern Copper Corporation0.41% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| LINLinde Plc0.41% weight | Industrydraft | Track whether pricing, volume, and spreads support earnings recovery. | Volume growthPrice-cost spreadEBITDA marginCapacity utilizationGuidance revision | Volume and spreads improve togetherManagement raises EBITDA outlookFeedstock or pricing pressure worsens | Commodity cycle downturnFeedstock inflationDemand weakness | ev_ebitdafcf_yieldmidcycle_ebitda |
| ENTGEntegris Inc0.41% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| TEVATeva Pharmaceutical Industries0.41% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| UUnity Software Inc0.41% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| AEVAAeva Technologies Inc0.40% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| RIOTRiot Platforms Inc0.40% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| QQnity Electronics Inc0.39% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| EQIXEquinix Inc0.37% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| LRCXLam Research Corp0.36% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| DFTXDefinium Therapeutics Inc.0.32% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| BLTEBelite Bio Inc0.31% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| RSPInvesco S&P 500 Equal Weight E0.30% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| TXG10X Genomics Inc0.30% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| WABWestinghouse Air Brake Technol0.29% weight | Sectordraft | Confirm that backlog, margins, and guidance support continued earnings growth. | Orders/backlogOrganic revenue growthOperating marginBook-to-billGuidance revision | Orders/backlog and margins improveBook-to-bill remains above oneGuidance is raised | Industrial cycle slowdownSupply-chain issuesInput cost pressure | ntm_peev_ebitdafcf_yield |
| LLYLilly(Eli) & Co0.28% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| XENEXenon Pharmaceuticals Inc0.28% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| OLMAOlema Pharmaceuticals Inc0.24% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| RGENRepligen Corp0.20% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| RKTRocket Companies Inc0.20% weight | Sectordraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| BIDUBaidu Inc0.19% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| ARMArm Holdings plc0.19% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| CVNACarvana Co0.19% weight | Sectordraft | Confirm that demand and margins improve without excessive valuation pressure. | Same-store/revenue growthGross marginOperating marginTraffic/ordersGuidance revision | Revenue and traffic/orders accelerateMargins expandGuidance improves | Consumer slowdownPromotional intensityInput cost pressure | ntm_peev_ebitdantm_ev_sales |
| RDDTReddit Inc0.19% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| AAAlcoa Corp0.19% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| TMOThermo Fisher Scientific Inc0.18% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| DHRDanaher Corp0.18% weight | Sectordraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| FFIVF5 Inc0.18% weight | Sectordraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| VISTVista Energy S.A.B. de C.V0.16% weight | Industrydraft | Confirm that cash flow and capital allocation stay strong across the commodity cycle. | Oil/gas price realizationProduction growthFree cash flowCapex disciplineBuyback/dividend | Oil/gas price backdrop improvesProduction and FCF beat expectationsBuyback or dividend intensity rises | Oil price declinePolitical/regulatory riskCapex inflation | ev_ebitdafcf_yieldnet_debt_to_ebitda |
| SKESkeena Resources Ltd0.15% weight | Sectordraft | Confirm that realized prices, volumes, and margins support a materials-cycle thesis. | Realized priceVolume growthCash costFree cash flowGuidance revision | Commodity price and volume improve togetherCash costs fall or FCF risesManagement raises outlook | Commodity price declineCost inflationDemand slowdown | ev_ebitdafcf_yieldprice_to_book |
| JBSJBS N.V.0.15% weight | Draftdraft | Identify whether the company's core operating drivers are improving enough to support continued ownership. | Revenue growthMargin trendFree cash flowGuidance revisionValuation pressure | Growth and margin outlook improvesManagement raises guidanceCash flow improves | Growth slowdownMargin pressureHigh valuation | ntm_pentm_ev_salesev_ebitda |
| GLUEMonte Rosa Therapeutics Inc0.14% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| RLAYRelay Therapeutics Inc0.13% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| DBVTDBV Technologies0.12% weight | Industrydraft | Confirm that product demand and pipeline/regulatory progress offset pricing, patent, and litigation risks. | Product revenue growthPipeline milestonesMargin/cost progressBalance sheetGuidance revision | Product sales beat and guidance is raisedPipeline/regulatory event improves probability of successLitigation, pricing, or patent risk worsens | Patent cliffsPricing pressureRegulatory setbacks | ntm_peev_ebitdafree_cash_flow_yield |
| CCCCCC Intelligent Solutions Hold0.12% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| UWMCUWM Holdings Corporation0.11% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| NVTSNavitas Semiconductor Corp0.11% weight | Industrydraft | Confirm that demand, margins, and inventory are improving enough to justify continued exposure. | Revenue growthGross marginAI/data-center exposureInventory/backlogGuidance revision | Revenue and gross margin beat with raised outlookAI or data-center demand commentary improvesInventory correction ends or backlog strengthens | Semiconductor cycle rolloverCustomer concentrationInventory correction | ntm_pentm_ev_salesgross_margin_adjusted_growth |
| SOLSSolstice Advanced Materials In0.11% weight | Industrydraft | Track whether pricing, volume, and spreads support earnings recovery. | Volume growthPrice-cost spreadEBITDA marginCapacity utilizationGuidance revision | Volume and spreads improve togetherManagement raises EBITDA outlookFeedstock or pricing pressure worsens | Commodity cycle downturnFeedstock inflationDemand weakness | ev_ebitdafcf_yieldmidcycle_ebitda |
| FTAIFTAI Aviation Ltd0.10% weight | Industrydraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| BEAMBeam Therapeutics Inc0.10% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
| AURAurora Innovation Inc0.08% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| IRENIREN Ltd.0.08% weight | Industrydraft | Confirm that growth quality and profitability are improving without excessive valuation pressure. | Revenue growthRetention/usageOperating marginFCF marginGuidance revision | Revenue or usage growth reacceleratesOperating margin or FCF margin expandsAI/product commentary improves demand outlook | Growth decelerationHigh valuationCompetition | ntm_ev_salesrule_of_40fcf_yield |
| GGALGrupo Financiero Galicia0.06% weight | Sectordraft | Track the macro variables and underlying exposure that explain the ETF or financial vehicle. | Underlying index returnCurrency/rate signalCommodity/country signalFlows/liquidityRelative strength | Underlying market breaks out or rolls overCurrency/rate/commodity backdrop shiftsETF liquidity or flows become stressed | Country riskCurrency riskLiquidity risk | nav_discount_premiumunderlying_perelative_strength |
| WVEWave Life Sciences Ltd.0.02% weight | Industrydraft | Track whether the key product, pipeline, or platform is being validated by data and commercial execution. | Clinical/platform milestonesRevenue/volume growthGross marginCash runwayGuidance/pipeline update | Clinical data, FDA, or reimbursement update changes probability of successCommercial launch or test volume acceleratesCash burn improves or financing risk falls | Clinical failureRegulatory delayDilution | ev_salescash_runwayrisk_adjusted_pipeline_value |
These draft templates define each stock's operating drivers. They do not yet score recent earnings or news; that signal layer is the next step.